Author(s): Seetha Monrad, M.D., 2009

License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use.

Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
Citation Key
for more information see: http://open.umich.edu/wiki/CitationPolicy

Use + Share + Adapt

{ Content the copyright holder, author, or law permits you to use, share and adapt. }

- **Public Domain – Government**: Works that are produced by the U.S. Government. (17 USC § 105)
- **Public Domain – Expired**: Works that are no longer protected due to an expired copyright term.
- **Public Domain – Self Dedicated**: Works that a copyright holder has dedicated to the public domain.
- **Creative Commons – Zero Waiver**
- **Creative Commons – Attribution License**
- **Creative Commons – Attribution Share Alike License**
- **Creative Commons – Attribution Noncommercial License**
- **Creative Commons – Attribution Noncommercial Share Alike License**
- **GNU – Free Documentation License**

Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }

- **Public Domain – Ineligible**: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ*

{ Content Open.Michigan has used under a Fair Use determination. }

- **Fair Use**: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ*

Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should **do your own independent analysis** to determine whether or not your use will be Fair.
Autoantibodies and Rheumatologic Diseases: When and How to Use Laboratory tests

Seetha Monrad M.D.
Case 1

• 23 year old woman is referred to your clinic to “rule out lupus”

• History is notable for no photosensitivity, unusual rashes, oral ulcers, pleurisy, hair loss, or arthralgias

• On family history, has an aunt with Sjögren’s disease and a cousin with lupus

• Physical exam completely within normal limits

• Outside labwork: ANA 1:40

• Does she have SLE?
Autoantibodies

- Autoantibodies are immunoglobulins that bind to antigens originating in the same individual or species (autoantigens).
- Autoantigens include self molecules in the nucleus, cytoplasm, and cell surface.
- Many autoantibodies are associated with autoimmune diseases but the majority of autoantibodies have no known pathogenic role in any disease.
Antinuclear antibodies (ANA)

- Serologic hallmark of autoimmune diseases
- May bind DNA, RNA, nuclear proteins, protein-nucleic acid complexes
Principle of Indirect Immunofluorescence

1. Step 1: Cell nucleus and cytoplasm are labeled with antibodies.
2. Step 2: Antibodies bind to the glass slide, and fluorescently labeled antibodies are added to detect the bound antibodies.

ANA in non-rheumatologic diseases

- Hashimoto’s thyroiditis 40-50%
- Graves’ disease 50%
- Autoimmune hepatitis 60-90%
- Primary biliary cirrhosis 10-40%
- Chronic infectious diseases
  - Mononucleosis
  - Hepatitis C
  - Subacute bacterial endocarditis
  - TB
- **Normal Population** 5%
  - Higher in women, elderly
ANA in rheumatologic diseases

- SLE
- Drug-induced SLE
- RA (40%)
- Polymyositis/dermatomyositis (75%)
- What else?
Case 2

• A 40 year old woman presents with “hand pain”
• 6 months ago noted fingers changing colors, associated with pain
• Two months ago fingers became diffusely swollen, painful, difficult to move
• Noticing a little difficulty breathing
Systemic sclerosis

- Generalized disorder of connective tissue
- Characterized clinically by thickening and fibrosis of the skin (scleroderma)
- Distinctive forms of involvement of internal organs, notably the heart, lungs, kidneys, and gastrointestinal tract

scleroderma (Greek skleros ["hard"] + derma ["skin"])

"Scleroderma is one of the most terrible of all human ills. Like Tithonus to "wither slowly", and like him to be "beaten down and marred and wasted" until one is literally a mummy, encased in an ever shrinking, slowly contracting skin of steel, is a fate not pictured in any tragedy, ancient or modern."

- Osler, 1898
Classification

• **With diffuse cutaneous scleroderma**
  – Skin thickening present on the trunk in addition to face, proximal and distal extremities

• **With limited cutaneous scleroderma**
  – Skin thickening limited to sites distal to the elbow and knee but also involving the face and neck
  – Synonym: CREST syndrome (C, calcinosis; R, Raynaud's phenomenon; E, esophageal dysmotility; S, sclerodactyly; T,
Raynaud’s phenomenon

Triphasic color change: white, blue, red

Primary: common, benign, affects young women, precipitated by cold/stress

More likely to be secondary (pathologic) with: older age at onset, few fingers involved, prolonged painful ischemic episodes, abnormal nailfold capillary exam
Nailfold capillaroscopy

- Top: normal symmetric hairpin loops.
- Center:
  - tortuosity and redundancy of multiple capillary loops
  - might be encountered in both systemic sclerosis and other connective tissue disorders
- Bottom: disease-specific changes of systemic sclerosis, including a paucity of capillary loops (drop-out) and grossly dilated loops
Sclerodactyly

American College of Rheumatology (Both Images)
Digital ischemia
Calcinosis cutis
Cutaneous findings
Vasculopathy

Marked intimal hyperplasia causing lumenal occlusion

Scleroderma renal crisis: used to be the most feared complication and major cause of mortality – less common now
Pulmonary fibrosis and pulmonary hypertension
Gastrointestinal manifestations
Systemic Sclerosis

Autoantibodies

- **ANA**: 85%
- Anti-centromere: limited cutaneous
- Anti-Scl-70: diffuse scleroderma

Treatments

- GERD: PPI, non-drug therapies
- GI dysmotility: prokinetics
- Alveolitis: steroids, immunosuppressives
- Pulm HTN: similar to idiopathic
- Renal: ACE inhibitors
Raynaud’s phenomenon

• Treatment
  – Behavioral modification
    • Warm extremities AND core
    • Avoid smoking
  – Medications
    • Calcium channel blockers (felodipine, amlodipine)
    • ACE-inhibitors, angiotensin receptor blockers
    • Selective serotonin reuptake inhibitors
    • Phosphodiesterase inhibitors (sildenafil)
    • Topical nitrates
  – For severe (digital ischemia):  
    • Iloprost (intravenous prostacyclin agonist)
    • Bosentan (endothelin receptor blocker)
    • Sympathetic block / sympathectomy
Case 4

- A 60 year old woman comes to clinic to establish care
- No major complaints
- On careful ROS, you elicit that she often feels like she has gravel in her eyes, and uses eye drops four times a day
- She also has a history of numerous dental caries
- Exam:
  - Parotid gland enlargement
  - Conjunctival erythema
  - Extremely dry oral mucosa
Sjögren’s Syndrome

- Affects 500,000 to 2 million people in US
- A major women’s health issue
- Of increasingly important in an aging population
- Often overlooked and neglected
- Holds clues for both autoimmunity and cancer

- Dry mouth and dry eyes (oral and ocular sicca)
- Extraglandular manifestations
- Overlap with other diseases
  - Rheumatic: RA, SLE
  - Thyroiditis, primary biliary cirrhosis, multiple sclerosis
  - Hepatitis C
- Lymphoproliferative disorder
Sjögren’s Syndrome: Ocular manifestations

- Foreign body sensation, like sand in eyes
- Inability to tolerate contact lenses
- Redness, ocular fatigue
- Thick mucous strands in the morning
- Objective: Schirmer’s testing, Rose-Bengal staining
Sjögren’s Syndrome: Oral manifestations

- Dry mouth; carry water bottles, water at bedside
- “Cracker sign”: unable to eat dry food without liquid
- Poor dentition; unable to wear dentures
- Oral candidiasis
Classification Criteria for Sjögren’s Syndrome*

I  Ocular symptoms
II  Oral symptoms
III  Ocular signs
IV  Histopathology
V  Salivary gland involvement
VI  Autoantibodies

*The presence of 4 out of 6 criteria, including 1 objective criterion (histopathology or autoantibodies). Exclusions include HIV infection, lymphoma, GVHD, sarcoidosis.
Autoantibodies in Sjogren’s syndrome

- **ANA:** ~67%
- **Anti Ro/SSA:**
  - Recognize cellular proteins with M.W. ~52-60kDa
  - Associated with Sjogren’s (75% primary, 15% secondary), SLE (50%)
  - Subacute cutaneous lupus, neonatal lupus and congenital heartblock
  - 0.1-0.5% normal adults
- **Anti-La/SSB:**
  - Almost always associated with anti-Ro (except in primary biliary cirrhosis and autoimmune hepatitis)
  - Associated with Sjogren’s (40%), SLE (15%), and neonatal lupus
Anti-Ro/La and Neonatal Lupus Syndromes

- From transplacental passage of maternal anti-Ro/La in the perinatal period
- Transient rash
- Congenital heart block
  - ~1% rate of CHB in Ro+ve mothers
  - ~15% rate of CHB in second child
- most often identified between 18-24 wks gestation

- ~50% of asymptomatic mothers with children who have neonatal lupus will eventually develop an autoimmune disease such as lupus or Sjogren’s
Treatment of Sjögren’s Syndrome

- **Ocular manifestations**
  - Artificial tears
  - Punctal plugging
  - Topical cyclosporine

- **Oral sicca**
  - Good dental hygiene
  - Avoid anticholinergic drugs
  - Saliva substitutes
  - Stimulate salivary flow
    - Sugar free candy/gum
    - Muscarinic agonists
  - Treat oral candidiasis

- **NSAIDs**
- **Corticosteroids**
- **Hydroxychloroquine**
- **Immunosuppressives** e.g. methotrexate, cyclophosphamide
Back to case 1....

- 23 year old woman is referred to your clinic to “rule out lupus”
- History is notable for no photosensitivity, unusual rashes, oral ulcers, pleurisy, hair loss, or arthralgias
- On family history, has an aunt with Sjögren’s disease and a cousin with lupus
- Physical exam completely within normal limits
- Outside labwork: ANA 1:40

- Patient does not have lupus
- ANA is low titer; likely false positive
- Alternately, may reflect autoimmunity in her family
Case 4

• The same woman returns two years later, complaining of fatigue, arthralgias
• ANA drawn 2 weeks ago was >1:2560

• What lab would be consistent as part of a diagnosis of lupus?
  1. Anti-Ro Ab
  2. Anti-phospholipid Ab
  3. Anti – dsDNA
  4. Anti – Sm
  5. Low C3
Specific antinuclear antibodies

- Anti-dsDNA antibodies
  - Highly specific for SLE
  - Specific assays
    - Farr
    - Crithidia
  - Levels fluctuate over time
  - Serum levels may correlate with renal disease activities
  - Have been isolated from glomerular elutes from patients with active nephritis → Pathogenic
Specific antinuclear antibodies

- ENA: extractable nuclear antigens
  - Anti-Sm
    - Smith antigen: snRNP (small nuclear ribonucleoprotein) core proteins
    - Highly specific for SLE; sensitivity 30%
    - Levels remain fairly constant and do not fluctuate with disease activity
  - Anti-RNP
    - Present in SLE (30-40%)
    - High titers → mixed connective tissue disease
Anti-Histone Antibodies

• >95% cases of drug-induced lupus
  – Procainamide
  – Hydralazine
  – Phenytoin
  – Isoniazid

• Also seen in idiopathic SLE (70%)
Anti-Phospholipid (APL) Antibodies

- Can be ‘primary’ or associated with a connective tissue disease e.g. SLE
- 4 subtypes
  - False positive VDRL
  - Lupus anticoagulants
  - Anticardiolipin antibodies
  - Anti-β2-glycoprotein antibodies
- Associated with arterial/venous thrombosis, recurrent fetal loss, thrombocytopenia
Clinical use of complements in SLE

- C3, C4
- Low levels can indicate active disease
- Don’t order CH50; screens for deficiency in complement cascade
- Low complements can also be seen in other conditions (cryoglobulinemic vasculitis, Sjogren’s etc.)
Other labs often ordered
Erythrocyte sedimentation rate (ESR)

- The rate (mm/hr) at which anticoagulated blood settles in a special tube (Westegren tube)
- Estimate for normal value:
  \[ \text{normal value} = \frac{\text{age(yrs)} + 10 \text{ (if female)}}{2} \]
- Inflammation → increased plasma proteins and fibrinogen (acute phase reactants) → cause RBCs to stick together and fall faster → higher ESR
ESR

• Indirect marker of inflammation
  – dependent on
    • size, shape and number of RBCs
    • presence of other plasma components (ie immunoglobulins)
  – Affected by
    • age and gender
  – Responds slowly to inflammatory stimuli
Inflammatory markers

• Acute phase proteins
  – Produced by hepatocytes
  – Acute phase response: increase in serum proteins in response to cytokine release (esp. IL-6) from monocytes and macrophages in inflammatory states
  – CRP:
    • Precise function unknown; activates complement, but also anti-inflammatory
    • Rapidly fluctuates in response to inflammation
  – Others: serum amyloid A (SAA), ferritin
Summary

- Autoantibodies are confirmatory but rarely diagnostic
- Often are epiphenomena
- Know which lab abnormalities tend to be present in different diseases, but don’t rely on them exclusively